187 related articles for article (PubMed ID: 17681004)
1. The suppression of gastro-oesophageal reflux by alginates.
Dettmar PW; Hampson FC; Taubel J; Lorch U; Johnstone LM; Sykes J; Berry PJ
Int J Clin Pract; 2007 Oct; 61(10):1654-62. PubMed ID: 17681004
[TBL] [Abstract][Full Text] [Related]
2. Post-prandial reflux suppression by a raft-forming alginate (Gaviscon Advance) compared to a simple antacid documented by magnetic resonance imaging and pH-impedance monitoring: mechanistic assessment in healthy volunteers and randomised, controlled, double-blind study in reflux patients.
Sweis R; Kaufman E; Anggiansah A; Wong T; Dettmar P; Fried M; Schwizer W; Avvari RK; Pal A; Fox M
Aliment Pharmacol Ther; 2013 Jun; 37(11):1093-102. PubMed ID: 23600790
[TBL] [Abstract][Full Text] [Related]
3. Clinical and laboratory studies of the antacid and raft-forming properties of Rennie alginate suspension.
Tytgat GN; Simoneau G
Aliment Pharmacol Ther; 2006 Mar; 23(6):759-65. PubMed ID: 16556178
[TBL] [Abstract][Full Text] [Related]
4. Effect of Gaviscon Infant on gastro-oesophageal reflux in infants assessed by combined intraluminal impedance/pH.
Del Buono R; Wenzl TG; Ball G; Keady S; Thomson M
Arch Dis Child; 2005 May; 90(5):460-3. PubMed ID: 15851425
[TBL] [Abstract][Full Text] [Related]
5. The efficacy of sodium alginate (Gaviscon) for the treatment of gastro-oesophageal reflux in preterm infants.
Corvaglia L; Aceti A; Mariani E; De Giorgi M; Capretti MG; Faldella G
Aliment Pharmacol Ther; 2011 Feb; 33(4):466-70. PubMed ID: 21158879
[TBL] [Abstract][Full Text] [Related]
6. [Treatment with sodium alginate of gastroesophageal reflux disease in childhood: efficacy and tolerance assessment].
Maestri L
Pediatr Med Chir; 2001; 23(3-4):187-9. PubMed ID: 11723856
[TBL] [Abstract][Full Text] [Related]
7. An evaluation of the antireflux properties of sodium alginate by means of combined multichannel intraluminal impedance and pH-metry.
Zentilin P; Dulbecco P; Savarino E; Parodi A; Iiritano E; Bilardi C; Reglioni S; Vigneri S; Savarino V
Aliment Pharmacol Ther; 2005 Jan; 21(1):29-34. PubMed ID: 15644042
[TBL] [Abstract][Full Text] [Related]
8. Gaviscon for gastro-oesophageal reflux in infants: a poorly effective treatment?
Cresi F; Savino F; Marinaccio C; Silvestro L
Arch Dis Child; 2006 Jan; 91(1):93. PubMed ID: 16371388
[No Abstract] [Full Text] [Related]
9. Gaviscon Double Action Liquid (antacid & alginate) is more effective than antacid in controlling post-prandial oesophageal acid exposure in GERD patients: a double-blind crossover study.
De Ruigh A; Roman S; Chen J; Pandolfino JE; Kahrilas PJ
Aliment Pharmacol Ther; 2014 Sep; 40(5):531-7. PubMed ID: 25041141
[TBL] [Abstract][Full Text] [Related]
10. Combined cimetidine-alginate antacid therapy versus single agent treatment for reflux oesophagitis: results of prospective double-blind randomised clinical trial.
Eriksen CA; Cheadle WG; Cranford CA; Cuschieri A
Ann Chir Gynaecol; 1988; 77(4):133-7. PubMed ID: 2855391
[TBL] [Abstract][Full Text] [Related]
11. [Treatment of gastro-esophageal reflux using a potable gaviscon suspension].
Guerre J; Neuman M; Bouchet J
Med Chir Dig; 1982; 11(4):289-95. PubMed ID: 6287126
[No Abstract] [Full Text] [Related]
12. Comparative study of Algicon versus Gaviscon in symptomatic gastro-oesophageal reflux.
Ward AE
Br J Clin Pract Suppl; 1989 Feb; 66():52-5; discussion 61-4. PubMed ID: 2556176
[No Abstract] [Full Text] [Related]
13. [Gaviscon in reflux symptoms. Results of a drug monitoring study].
Hutt HJ; Tauber O; Flach D
Fortschr Med; 1990 Oct; 108(31):598-600. PubMed ID: 2258131
[TBL] [Abstract][Full Text] [Related]
14. Randomised clinical trial: the effectiveness of Gaviscon Advance vs non-alginate antacid in suppression of acid pocket and post-prandial reflux in obese individuals after late-night supper.
Deraman MA; Abdul Hafidz MI; Lawenko RM; Ma ZF; Wong MS; Coyle C; Lee YY
Aliment Pharmacol Ther; 2020 Jun; 51(11):1014-1021. PubMed ID: 32343001
[TBL] [Abstract][Full Text] [Related]
15. Randomised clinical trial: relief of upper gastrointestinal symptoms by an acid pocket-targeting alginate-antacid (Gaviscon Double Action) - a double-blind, placebo-controlled, pilot study in gastro-oesophageal reflux disease.
Thomas E; Wade A; Crawford G; Jenner B; Levinson N; Wilkinson J
Aliment Pharmacol Ther; 2014 Mar; 39(6):595-602. PubMed ID: 24471505
[TBL] [Abstract][Full Text] [Related]
16. Two placebo-controlled crossover studies in healthy subjects to evaluate gastric acid neutralization by an alginate-antacid formulation (Gaviscon Double Action).
Wilkinson J; Abd-Elaziz K; den Daas I; Wemer J; van Haastert M; Hodgkinson V; Foster M; Coyle C
Drug Dev Ind Pharm; 2019 Mar; 45(3):430-438. PubMed ID: 30470147
[TBL] [Abstract][Full Text] [Related]
17. A comparison between cisapride and Gaviscon with Carobel in the treatment of gastro-oesophageal reflux in infancy.
Greally P; Hampton FJ; MacFadyen UM; Simpson H
Ir Med J; 1992; 85(4 Suppl):14. PubMed ID: 1490841
[No Abstract] [Full Text] [Related]
18. [Can acid pocket-targeting alginate-antacid (Gaviscon Double Action) relieve upper gastrointestinal symptoms in gastro-oesophageal reflux disease?].
Kim SE; Park MI
Korean J Gastroenterol; 2014 Jun; 63(6):386-8. PubMed ID: 25097964
[No Abstract] [Full Text] [Related]
19. [Alginate-containing preparation gaviscon for patients with gastroesophaginal reflux complicated with chronic pancreatitis: pathogenetic substantiation of clinical use prospects].
Uspenskiĭ IuP; Pakhomova IG; Bubiakina VN
Eksp Klin Gastroenterol; 2008; (1):96-101. PubMed ID: 19145860
[No Abstract] [Full Text] [Related]
20. Algicon in the management of gastro-oesophageal reflux.
Lambert JR; Korman MG; Nicholson L
Br J Clin Pract Suppl; 1989 Feb; 66():56-8; discussion 61-4. PubMed ID: 2556177
[No Abstract] [Full Text] [Related]
[Next] [New Search]
